These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36165374)

  • 1. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 36165374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 33423842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population.
    Fabrizi F; Cerutti R; Nardelli L; Tripodi F; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):49-56. PubMed ID: 31327620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial.
    Fabrizi F; Cerutti R; Garcia-Agudo R; Bellincioni C; Porata G; Frontini G; Aoufi-Rabih S; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):905-912. PubMed ID: 32144074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
    Surquin M; Tielemans C; Nortier J; Jadoul M; Peeters P; Ryba M; Roznovsky L; Domán J; Barthelemy X; Crasta PD; Messier M; Houard S
    Hum Vaccin; 2011 Sep; 7(9):913-8. PubMed ID: 21892006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population.
    Fabrizi F; Martin P; Messa P
    Int J Artif Organs; 2015 Dec; 38(12):625-31. PubMed ID: 26821784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
    Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
    Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
    Surquin M; Tielemans CL; Kulcsár I; Ryba M; Vörös P; Mat O; Treille S; Dhaene M; Stolear JC; Kuriyakose SO; Leyssen MX; Houard SA
    Kidney Int; 2010 Feb; 77(3):247-55. PubMed ID: 19940840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprotection achieved with standard four-dose schedule of hepatitis B vaccine in people with chronic kidney disease: A real-life data.
    Singh S; Mishra AK; Yachha M; Singh TP; Katiyar H; Kaul A; Dhiman RK; Bhadauria DS; Goel A
    Indian J Gastroenterol; 2024 Sep; ():. PubMed ID: 39298024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
    Tielemans CL; Vlasak J; Kosa D; Billiouw JM; Verpooten GA; Mezei I; Ryba M; Peeters PC; Mat O; Jadoul MY; Polakovic V; Dhaene M; Treille S; Kuriyakose SO; Leyssen M; Houard SA; Surquin M
    Vaccine; 2011 Feb; 29(6):1159-66. PubMed ID: 21167859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients.
    Kong NC; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; Calbo-Torrecillas F; López de Novales E; Srinivasa K; Stoffel M; Hoet B
    Kidney Int; 2008 Apr; 73(7):856-62. PubMed ID: 18160963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of compulsory and booster doses of hepatitis B vaccine among children in Cairo, Egypt.
    Salama I; Sami S; Saleh R; Mohsen A; Elserougy S; Emam H; Said Z
    J Egypt Public Health Assoc; 2017 Jun; 92(2):77-85. PubMed ID: 30184404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease.
    Fabrizi F; Dixit V; Magnini M; Elli A; Martin P
    Aliment Pharmacol Ther; 2006 Aug; 24(3):497-506. PubMed ID: 16886915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Controlled Trial of Seroconversion After 20 Mg versus 40 mg Intramuscular Hepatitis B Virus Vaccination in Patients with Chronic Kidney Disease Stage 3.
    Krairittichai U; Sethakarun S
    J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S1-7. PubMed ID: 29926711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation.
    Fabrizi F; Andrulli S; Bacchini G; Corti M; Locatelli F
    Nephrol Dial Transplant; 1997 Jun; 12(6):1204-11. PubMed ID: 9198052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.